HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers

HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers

Triple negative breast cancers (TNBCs) represent 15–20% of all breast cancers and are associated with higher recurrence and distant metastasis rate. Standard of care for early stage TNBC is anthracyclines combined with cyclophosphamide (AC) followed by taxanes, in the neo‐adjuvant or adjuvant settin...

Full description

Bibliographic Details
Main Authors: Rania El‐Botty, Sophie Vacher, Juliette Mainguené, Adrien Briaux, Sabrina Ibadioune, Ahmed Dahmani, Elodie Montaudon, Fariba Nemati, Léa Huguet, Laura Sourd, Ludivine Morriset, Sophie Château‐Joubert, Thierry Dubois, Virginie Maire, Rosette Lidereau, Audrey Rapinat, David Gentien, Florence Coussy, Ivan Bièche, Elisabetta Marangoni
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Molecular Oncology
Subjects:
AC sensitivity
biomarker
HORMAD1
TNBC
Online Access:https://doi.org/10.1002/1878-0261.13412

Similar Items

Similar Items